Current Report Filing (8-k)
October 07 2016 - 4:49PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 6, 2016
CORBUS
PHARMACEUTICALS HOLDINGS, INC.
|
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
001-37348
|
|
46-4348039
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
100
River Ridge Drive, Norwood, MA
|
|
02062
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(617) 963-0100
Not
Applicable
|
(Former
name or former address, if changed since last report.)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
|
On
October 6, 2016, the Compensation Committee of the Board of Directors (the “Committee”) of Corbus Pharmaceuticals
Holdings, Inc. (the “Company”)
approved equity compensation awards for the Company’s
executive officers, Yuval Cohen, Ph.D., Chief Executive Officer; Barbara White, M.D., Chief Medical Officer; Mark Tepper, Ph.D.,
President and Chief Scientific Officer; and Sean Moran, Chief Financial Officer.
The
Committee approved an award of 150,000 options (the “Options”) to purchase shares of the Company’s common stock,
par value $0.0001 per share, to each of Dr. Cohen, Dr. White, Dr. Tepper and Mr. Moran. The Options were granted in accordance
with the terms of the Company’s 2014 Equity Compensation Plan (the “Plan”). The Options have an exercise price
of $8.71 and will vest 25% on the one year anniversary of the grant date and the remainder in equal monthly installments over
three years, with full acceleration of vesting upon a change in control (as defined in the Plan). The Options represent a portion
of the annual equity award that the Company expects to pay to the executive officers in early 2017 for performance in 2016. As
it did in 2015, the Committee intends to engage an independent compensation consultant to determine the amount of compensation
to be paid to the Company’s executive officers, including cash and equity bonuses to be paid to the Company’s executive
officers in early 2017 for performance in 2016.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
CORBUS
PHARMACEUTICALS HOLDINGS, INC.
|
|
|
|
Dated: October
7, 2016
|
By:
|
/s/
Yuval Cohen
|
|
Name:
|
Yuval
Cohen
|
|
Title:
|
Chief
Executive Officer
|
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Apr 2023 to Apr 2024